Clinical Trial Update: A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age [Phase 1, Phase 2]

View source ↗

Summary

The study reports the completion of a Phase 1/2 trial evaluating the safety, tolerability, and immune response of multiple doses of the investigational mRNA vac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mpox
• Smallpox

Drugs mentioned

• mRNA-1769

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Smallpox, Mpox | Phase 1, Phase 2 | Status: COMPLETED